Barclays’s Cytokinetics CYTK Stock Holding History

Barclays’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.9M	Sell	104,700 -27,500	-21%	-$1.75M	﹤0.01%	1637
2025 Q4	$8.4M	Sell	132,200 -400	-0.3%	-$24.9K	﹤0.01%	1818
2025 Q3	$7.29M	Buy	132,600 +132,400	+66,200%	+$5.45M	﹤0.01%	1920
2025 Q2	$6.61K	Buy	+200	New	+$6.96K	﹤0.01%	4950
2025 Q1	–	Sell	-10,000	Closed	-$470K	–	5313
2024 Q4	$470K	Hold	10,000	–	–	﹤0.01%	3861
2024 Q3	$528K	Sell	10,000 -70,000	-88%	-$3.9M	﹤0.01%	3743
2024 Q2	$4.33M	Buy	80,000 +52,000	+186%	+$3.14M	﹤0.01%	1630
2024 Q1	$1.96M	Sell	28,000 -677,800	-96%	-$52.4M	﹤0.01%	2586
2023 Q4	$58.9M	Buy	705,800 +688,000	+3,865%	+$24.9M	0.02%	593
2023 Q3	$524K	Buy	+17,800	New	+$593K	﹤0.01%	2784
2020 Q4	–	Sell	-5,500	Closed	-$119K	–	4928
2020 Q3	$119K	Buy	+5,500	New	+$129K	﹤0.01%	4153
2017 Q4	–	Sell	-50,500	Closed	-$732K	–	6945
2017 Q3	$732K	Buy	+50,500	New	+$690K	﹤0.01%	3274
2014 Q2	–	Sell	-200	Closed	-$2K	–	7626
2014 Q1	$2K	Buy	+200	New	+$1.81K	﹤0.01%	7395

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays's CYTK Position: Q1 2026 in Review

Barclays reduced its Cytokinetics (CYTK) stake by 77% in Q1 2026, selling an estimated $16.8M and leaving 79,159 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Barclays first reported a position in CYTK in Q3 2013 and has held it in 51 quarters since. The position peaked at $53.4M in Q1 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Barclays held 79,159 shares of Cytokinetics worth $5.22M as of Q1 2026.
Barclays sold 264,299 Cytokinetics shares in Q1 2026, an estimated $16.8M.
Cytokinetics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1793 holding.
Barclays first reported a position in Cytokinetics in Q3 2013 and has held it in 51 quarters since.
Barclays's Cytokinetics position peaked at $53.4M in Q1 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.